EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Laryngeal Cancer Microbiome Study Reveals Parvimonas and Campylobacter as Potential Therapy Targets

Hetal Lad, Avi Shah, Emma R. Thompson, Sumayya Javid, Ruey Horng Chee, Sydney Zaransky, Aatin Dhanda, Avleen Mudhar, Sagar Lamichhane, Abigail T. Chua, Kristy Bono, Jamie Bono, Rachel Kaye, W. Evan Johnson, Carla Cugini, Kenneth Yan

The Laryngoscope · 2026-11-05

DOI: 10.1002/lary.71027 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objective Laryngeal cancer accounts for 40% of head and neck malignancies and 1% of all cancer‐related deaths worldwide. We evaluated the laryngeal cancer microbiome to identify cancer‐specific genera as potential treatment targets. Methods A prospective study was conducted using 57 laryngeal mucosal samples from 24 treatment‐naive laryngeal cancer patients and 33 patients who were undergoing otolaryngological surgery unrelated to oral or laryngeal diseases (01/2023–09/2025). DNA was extracted and amplified in triplicate, targeting the V3/V4 region of the 16S rRNA gene, followed by paired‐end 2 × 300 bp sequencing on the Illumina NextSeq 2000. Amplicon sequence variants were identified via DADA2 and assigned to genera using a naive Bayes classifier. Two samples with zero classified read pairs were excluded. Results Most patients were male (87.5% cancer, 66.7% controls) and smokers (83.3% cancer, 54.5% controls). Cancer patients' core laryngeal microbiomes uniquely contained Parvimonas (3.67%; 95% CI: 0.70%–6.64%), and Campylobacter (1.12%; 95% CI: 0.60%–1.63%), while control patients' uniquely contained Corynebacterium (2.97%; 95% CI: 0.00%–7.67%) and Alloprevotella (1.34%; 95% CI: 0.64%–2.04%). Cancer samples were significantly enriched in 19 genera, notably Peptococcus (2.93, q = 0.0003), Campylobacter (1.68, q = 0.009), and Parvimonas (2.02, q = 0.03), compared to controls. Conclusions Laryngeal cancer patients' samples displayed microbial dysbiosis, with enrichment of microbes present in gastrointestinal cancers, cervical cancer, and inflammatory states; they also exhibited loss of immunoprotective taxa. These findings support that microbiome profiling can distinguish malignant mucosa and guide future studies targeting genera increased in cancer, including Parvimonas and Campylobacter . Level of Evidence 3.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →